AlphaQuest LLC Increases Stock Position in Dynavax Technologies Co. (NASDAQ:DVAX)

AlphaQuest LLC increased its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 10.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 23,437 shares of the biopharmaceutical company’s stock after purchasing an additional 2,172 shares during the quarter. AlphaQuest LLC’s holdings in Dynavax Technologies were worth $299,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. US Bancorp DE lifted its position in shares of Dynavax Technologies by 291.4% during the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 2,034 shares in the last quarter. Smartleaf Asset Management LLC increased its position in shares of Dynavax Technologies by 463.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 2,034 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Dynavax Technologies by 55.1% during the fourth quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock worth $52,000 after acquiring an additional 1,457 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in Dynavax Technologies during the fourth quarter worth $71,000. Finally, Nisa Investment Advisors LLC boosted its position in Dynavax Technologies by 19.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 1,076 shares during the last quarter. 96.96% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on DVAX. William Blair reiterated an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 21st. HC Wainwright restated a “buy” rating and set a $31.00 price objective on shares of Dynavax Technologies in a report on Friday, February 21st. StockNews.com upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Monday, February 24th. Finally, The Goldman Sachs Group lowered shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and decreased their price target for the stock from $15.00 to $12.00 in a research note on Tuesday, February 11th.

Dynavax Technologies Trading Up 1.3 %

Shares of DVAX opened at $13.87 on Friday. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $14.63. The business has a 50-day moving average of $13.11 and a 200 day moving average of $12.30. The firm has a market cap of $1.72 billion, a P/E ratio of 77.06 and a beta of 1.23. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

Dynavax Technologies (NASDAQ:DVAX) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, hitting the consensus estimate of $0.05. The firm had revenue of $72.03 million during the quarter, compared to the consensus estimate of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. As a group, research analysts forecast that Dynavax Technologies Co. will post 0.32 EPS for the current year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.